Cataldo Miranda Pilar, Gasevic Danijela, Trin Caroline, Stub Dion, Zoungas Sophia, Kaye David M, Orman Zhomart, Eliakundu Amminadab L, Talic Stella
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Centre for Global Health, Usher Institute, The University of Edinburgh, Edinburgh, United Kingdom.
JACC Adv. 2025 Mar;4(3):101582. doi: 10.1016/j.jacadv.2024.101582. Epub 2025 Jan 30.
Historical data strongly supported the benefits of beta-blocker therapy following a myocardial infarction (MI) for its efficacy in reducing mortality and morbidity. However, in the context of the progressive evolution of treatment strategies for MI patients, the apparent benefit of beta-blocker therapy is becoming less clear. In particular, its effectiveness in patients with preserved left ventricular ejection fraction is currently being challenged. Consequently, contemporary guidelines are now varying in their recommendations regarding the role of beta-blocker therapy in post-MI patients. This review aims to summarize and compare the largest and most influential studies from the prereperfusion era to modern practice regarding different health outcomes while highlighting the need for further research to clarify beta-blocker therapy's place in contemporary post-MI management.
历史数据有力地支持了心肌梗死（MI）后使用β受体阻滞剂治疗的益处，因为其在降低死亡率和发病率方面具有疗效。然而，在MI患者治疗策略不断演进的背景下，β受体阻滞剂治疗的明显益处正变得不那么清晰。特别是，其在左心室射血分数保留的患者中的有效性目前正受到挑战。因此，当代指南对于β受体阻滞剂治疗在MI后患者中的作用的建议各不相同。本综述旨在总结和比较从再灌注时代之前到现代实践中关于不同健康结局的最大且最具影响力的研究，同时强调需要进一步研究以明确β受体阻滞剂治疗在当代MI后管理中的地位。
